cell factory high flask t600 (Merck KGaA)
90
Structured Review
Merck KGaA
cell factory high flask t600
Cell Factory High Flask T600, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+factory+high+flask+t600/millicell+hy+t+600+three+layer+culture+flask/us10724014-278-6-11
Average 90 stars, based on 1 article reviews
Cell Factory High Flask T600, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+factory+high+flask+t600/millicell+hy+t+600+three+layer+culture+flask/us10724014-278-6-11
Average 90 stars, based on 1 article reviews
cell factory high flask t600 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Transfection:Article Title: Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Article Snippet: ar ch 3 1, 2 01 5 Achondroplasia is a rare genetic disease characterized by abnormal bone development, resulting in short stature.. It is caused by a single point mutation in the gene coding for fibroblast growth factor receptor 3 (FGFR3), which leads to prolonged activation upon ligand binding.. To prevent excessive intracellular signaling and rescue the symptoms of achondroplasia, we have developed a recombinant protein therapeutic approach using a soluble form of human FGFR3 (sFGFR3), which acts as a decoy receptor and prevents FGF from binding to mutant FGFR3. sFGFR3 was injected subcutaneously to newborn Fgfr3 mice—the mouse model of achondroplasia— twice per week throughout the growth period during 3 weeks. Article Title: Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders Article Snippet: Recombinant FLAG-sFGFR3 protein was produced by transient transfection using GeneJuice transfection reagent (Merck Millipore) in HEK 293 cells allowing all necessary post-translational modifications. .. Each transfection was performed in a Modification:Article Title: Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Article Snippet: ar ch 3 1, 2 01 5 Achondroplasia is a rare genetic disease characterized by abnormal bone development, resulting in short stature.. It is caused by a single point mutation in the gene coding for fibroblast growth factor receptor 3 (FGFR3), which leads to prolonged activation upon ligand binding.. To prevent excessive intracellular signaling and rescue the symptoms of achondroplasia, we have developed a recombinant protein therapeutic approach using a soluble form of human FGFR3 (sFGFR3), which acts as a decoy receptor and prevents FGF from binding to mutant FGFR3. sFGFR3 was injected subcutaneously to newborn Fgfr3 mice—the mouse model of achondroplasia— twice per week throughout the growth period during 3 weeks. |